Table 1 Patients clinical and biochemical characteristics before and after PCSK9i treatment

Body mass index (kg/m²)

28.5 ± 3.7

28.4 ± 3.9

Systolic blood pressure (mm Hg)

126 ± 14

124 ± 13

Diastolic blood pressure (mm Hg)

77 ± 8

79 ± 9

Total cholesterol (mmol/l)

4.26 ± 0.87

2.74 ± 0.95

HDL cholesterol (mmol/l)

1.17 ± 0.27

1.27 ± 0.32

LDL cholesterol (mmol/l)

2.33 ± 0.76

0.88 ± 0.82

Triglycerides (mmol/l)

1.68 ± 0.84

1.40 ± 0.87

Lipoprotein (a) (mg/l)

1444 (1199–1748)

1133 (820–1664)

Apolipoprotein B (g/l)

0.81 ± 0.22

0.46 ± 0.21

Apolipoprotein A1 (g/l)

1.34 ± 0.19

1.38 ± 0.19

hs-CRP (mg/l)

1.43 ± 1.44

1.69 ± 2.92

TNF-alpha (ng/l)

9.01 ± 14.30

9.92 ± 16.98

IL-6 (ng/l)

2.21 ± 2.08

2.19 ± 3.53

IL-8 (ng/l)

38.49 ± 156.25

29.34 ± 49.19

IL-10 (ng/l)

2.18 ± 9.57

1.52 ± 7.52

VCAM1 (mg/L)

0.72 ± 0.37

0.78 ± 0.41

TAFI (%)

99.18 ± 15.46

101.18 ± 15.40

PAI-1 antigen (ng/ml)

43.39 ± 29.26

54.49 ± 28.49

OCP (Abs-sum)

24.32 ± 5.37

25.21 ± 6.27

OFP (%)

71.54 ± 8.32

71.82 ± 8.21

OHP (Abs-sum)

6.89 ± 2.57

7.15 ± 2.94